Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ixazomib||Ninlaro||MLN9708||Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lymphoma||not applicable||Ixazomib||Preclinical||Actionable||In a preclinical study, Ixazomib (MLN9708) inhibited survival and induced apoptosis in T-cell lymphoma cell lines in culture, and reduced tumor volume in xenograft models (PMID: 26988986).||26988986|
|NPM1 exon12||acute myeloid leukemia||predicted - sensitive||Ixazomib||Case Reports/Case Series||Actionable||In a clinical study, Ixazomib (MLN9708) treatment resulted in significantly reduced peripheral blast cells in a NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia (AML) patient, and demonstrated selective toxicity towards NPMc+ AML cell lines in culture (PMID: 26634271).||26634271|
|Unknown unknown||Hodgkin's lymphoma||not applicable||Ixazomib||Preclinical||Actionable||In a preclinical study, Ixazomib (MLN9708) inhibited survival and induced apoptosis in Hodgkin's lymphoma cell lines in culture, and reduced tumor volume in xenograft models (PMID: 26988986).||26988986|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02440464||Phase II||Methotrexate + Tacrolimus Ixazomib Fludarabine + Melphalan Bortezomib||Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)||Active, not recruiting|
|NCT02504359||Phase I||Ixazomib Carmustine + Cytarabine + Etoposide + Melphalan Methotrexate + Tacrolimus||Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma||Active, not recruiting|